Skip to content
Martin and Harris Laboratories logo
Pre-IPOPublic Limited

Martin and Harris Laboratories Unlisted Share Price

Martin and Harris Laboratories Limited

Healthcare·Pharmaceuticals

CIN
U24239HR1993PLC033630
ISIN
INE03VV01015
Incorporated
22 Jul 1993
Registered state
Haryana

Key valuation

Market cap
₹358 Cr
P/E
5.4x
Debt / equity
0.0x
Shares outstanding
40,00,000

Indicative price

₹895prev ₹895

1M

+2.29%

6M

+5.29%

1Yr

-5.79%

Max

-26.94%

Updated 17 Nov 2026, 08:10

Prices shown are indicative, dealer-quoted and updated periodically — they are not exchange-traded prices and may differ from the price at which a transaction is finally executed.

Price history

Dated dealer-quote averages, plotted on a true time scale. There is no continuous trading behind these numbers.

-5.79%since 17 Nov 2025High ₹950Low ₹850321 dated snapshots

About Martin and Harris Laboratories

Martin and Harris Laboratories Limited is a Gurugram-based pharmaceutical and botanical products company that is part of the Apeejay Surrendra Group, one of India's older business groups. It was incorporated in the 1990s.

Alongside its pharmaceutical business, the company holds a sizeable investment portfolio of mutual funds and listed and unlisted shares, which accounts for much of its value.

Martin and Harris reported revenue of ₹107 crore and a net profit of ₹66 crore in FY2025, with a net worth of ₹707 crore.

Key highlights

  • Incorporated in 1996

Financial snapshot

FY2025

Revenue FY2025
₹107.43 Cr
EBITDA
₹88.97 Cr
PAT
₹66.30 Cr
Net worth
₹707.06 Cr
Total debt
₹13.00 Cr
Cash & equivalents
—
Operating cash flow
₹273.56 Cr
EPS
₹166

Management & board

  • HS

    Harnam Singh Thakur

    Nodal Officer, Director

    Since 2017
  • NU

    Nasim Uddin

    Director

    Since 2022
  • AC

    Ashok Chandra Sen

    Director

    Since 2023
  • VM

    Vivek Manohar Padgaonkar

    Director

    Since 2022

Reported financials · FY2021–FY2025

Figures in ₹ crore unless stated.

Revenue CAGR -10.5%PAT CAGR -21.8%
ParticularsFY2021FY2022FY2023FY2024FY2025YoYCAGR
Profit & loss
Revenue from operationsYoY -26.5%CAGR -10.5%168186205146107-26.5%-10.5%
Other incomeYoY +27.7%CAGR -28.5%16826243444+27.7%-28.5%
Total expensesYoY -16.1%CAGR -2.1%115119137125105-16.1%-2.1%
EBITDAYoY +47.3%CAGR -20.7%22597966089+47.3%-20.7%
Depreciation & amortisationYoY +5.7%CAGR +11.0%33455+5.7%+11.0%
EBITYoY +50.7%CAGR -21.5%22194925684+50.7%-21.5%
Finance costYoY +86.7%CAGR +53.8%00011+86.7%+53.8%
Profit before taxYoY +50.4%CAGR -21.7%22193925583+50.4%-21.7%
Tax expenseYoY +9.5%CAGR -22.2%4423241516+9.5%-22.2%
Profit after taxYoY +64.1%CAGR -21.8%17770684066+64.1%-21.8%
Earnings per shareYoY +64.1%CAGR -21.8%₹442₹176₹170₹101₹166+64.1%-21.8%
Balance sheet
Net worthYoY +11.9%CAGR +12.2%446—593632707+11.9%+12.2%
Total debtYoY +66.7%CAGR +30.4%554813+66.7%+30.4%
Current liabilitiesYoY -87.8%CAGR -34.5%18921524928535-87.8%-34.5%
Current assetsYoY +48.8%CAGR +22.6%280321370425633+48.8%+22.6%
Total assetsYoY +13.1%CAGR +12.9%461543615662749+13.1%+12.9%
Cash flow
Operating activitiesYoY +368.4%CAGR +64.0%38445158274+368.4%+64.0%
Investing activities-19-22-25-28-272——
Financing activities-17-20-23-273——
Free cash flowYoY +476.8%CAGR +72.0%30344045261+476.8%+72.0%
Net change in cashYoY +34.3%CAGR +22.3%22345+34.3%+22.3%

YoY compares the latest year with the one before it. CAGR runs from the oldest reported year to the latest. A dash means the year is missing, or the starting figure is zero or negative, so a percentage would mislead.

Margins, returns, liquidity, leverage and every other ratio from these figures: see Ratios

Revenue, EBITDA and PAT

₹ crore. A year with no reported figure is left out rather than drawn as zero.

056112168225FY2021 · Revenue: 168FY2021 · EBITDA: 225FY2021 · PAT: 177FY2021FY2022 · Revenue: 186FY2022 · EBITDA: 97FY2022 · PAT: 70FY2022FY2023 · Revenue: 205FY2023 · EBITDA: 96FY2023 · PAT: 68FY2023FY2024 · Revenue: 146FY2024 · EBITDA: 60FY2024 · PAT: 40FY2024FY2025 · Revenue: 107FY2025 · EBITDA: 89FY2025 · PAT: 66FY2025
056112168225FY2021 · Revenue: 168FY2021 · EBITDA: 225FY2021 · PAT: 177FY2021FY2022 · Revenue: 186FY2022 · EBITDA: 97FY2022 · PAT: 70FY2022FY2023 · Revenue: 205FY2023 · EBITDA: 96FY2023 · PAT: 68FY2023FY2024 · Revenue: 146FY2024 · EBITDA: 60FY2024 · PAT: 40FY2024FY2025 · Revenue: 107FY2025 · EBITDA: 89FY2025 · PAT: 66FY2025
  • Revenue
  • EBITDA
  • PAT

Every ratio here is worked out from the reported figures in the Financials tab, and valuation multiples from the indicative price in the header. Nothing is a stored value. A ratio the filings cannot support (a line not reported, or a zero or negative base) is left out or shown as —, never as a misleading number. Balance-sheet ratios use year-end figures.

Valuation multiples

What the indicative price pays for the latest year's earnings, book and cash. On FY2025 figures and the ₹895 indicative price.

Market cap
₹358 Cr
Enterprise value
₹371 Cr
Price / earnings (P/E)
5.40x
Price / book (P/B)
0.51x
Price / sales (P/S)
3.33x
Price / operating cash flow
1.31x
EV / EBITDA
4.17x
EV / EBIT
4.41x
EV / sales
3.45x
Earnings yield
18.5%
Free cash flow yield
72.8%
How these are worked out
Market cap
Indicative price × shares outstanding
Enterprise value
Market cap + debt − cash
Price / earnings (P/E)
Market cap ÷ PAT (profitable years only)
Price / book (P/B)
Market cap ÷ net worth
Price / sales (P/S)
Market cap ÷ revenue from operations
Price / operating cash flow
Market cap ÷ cash from operating activities
EV / EBITDA
Enterprise value ÷ EBITDA
EV / EBIT
Enterprise value ÷ (EBITDA − depreciation)
EV / sales
Enterprise value ÷ revenue from operations
Earnings yield
PAT ÷ market cap
Free cash flow yield
(Operating cash flow − capex) ÷ market cap

Shareholding pattern

As at 31 Mar 2025

Largest holder: Chang Investchem Private Limited 37.53%

37.5%20.7%20.1%21.7%

IPO / listing status

Pre-IPONot yet announced

The company has not announced IPO details such as a DRHP filing, an expected window or its bankers. This section will update once it does.

Research & news

Information currently unavailable

Nothing has been published on Martin and Harris Laboratories yet. Research, news and articles tagged with it will appear here when they are.

Browse all research

Documents

Private documents are shown locked and are released to verified clients on request.

DocumentTypeFY / dateAccess
Annual Report FY 2024-25Annual report · FY 2024-25 · 13.7 MB13.7 MBAnnual reportFY 2024-25ViewDownload
Annual Report FY 2023-24Annual report · FY 2023-24 · 11.7 MB11.7 MBAnnual reportFY 2023-24ViewDownload

Martin and Harris Laboratories unlisted shares: FAQs

What is the Martin and Harris Laboratories unlisted share price today?

The indicative price of Martin and Harris Laboratories Limited shares is ₹895 per share, as of 17 Nov 2026. Unlisted shares have no exchange price: this figure reflects recent off-market deals and can differ from the price on a particular trade. The price history on this page shows how it has moved.

How can I buy Martin and Harris Laboratories unlisted shares?

Raise a buy enquiry on this page with the number of shares you want. Our desk confirms availability and the price, you pay from a bank account in your own name, and the shares are transferred to your demat account. You need a PAN and a demat account with any depository participant.

How can I sell Martin and Harris Laboratories shares?

Raise a sell enquiry with the number of shares you hold in demat. Once the price is agreed, you transfer the shares from your demat account and the money is paid to a bank account in your name.

Is Martin and Harris Laboratories planning an IPO?

Martin and Harris Laboratories Limited is currently at the "Pre-IPO" stage. No IPO date has been announced. A listing depends on the company and on regulatory approval.

What are Martin and Harris Laboratories's revenue and profit?

In FY25, Martin and Harris Laboratories Limited reported revenue of ₹107 Cr and a profit of ₹66 Cr, with a net worth of ₹707 Cr. The Financials section has the full statements for every year we hold.

Is it legal to buy unlisted shares in India?

Yes. Shares of unlisted public companies can be bought and sold off-market and transferred between demat accounts. They carry more risk than listed shares: prices are not set on an exchange, it can take time to find a buyer, and a listing is never guaranteed.

Is there a lock-in on Martin and Harris Laboratories shares after the IPO?

SEBI rules lock in shares held before an IPO for a period after listing, currently six months from allotment for most investors in a mainboard IPO. Shares bought now in the unlisted market would usually be covered by this lock-in.

How are gains on Martin and Harris Laboratories unlisted shares taxed?

Gains on unlisted shares held for more than 24 months are long-term capital gains; held for less, they are short-term and taxed at your slab rate. Check the current rates with a tax adviser before you sell.